{"id":744871,"date":"2014-12-18T07:30:00","date_gmt":"2014-12-18T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/"},"modified":"2023-03-22T00:04:47","modified_gmt":"2023-03-22T04:04:47","slug":"merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/","title":{"rendered":"Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers"},"content":{"rendered":"<p class=\"bwalignc\">       Acquisition Expands Merck\u2019s Oncology Portfolio with Novel Oral BET        Inhibitor, OTX015     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that it has acquired, through a subsidiary, OncoEthix, a<br \/>\n      Swiss-based privately held biotechnology company specializing in<br \/>\n      oncology drug development. Through the acquisition, Merck has gained an<br \/>\n      investigational, novel oral BET (bromodomain) inhibitor, OTX015, which<br \/>\n      is currently in Phase 1b studies for the treatment of hematological<br \/>\n      malignancies and advanced solid tumors.\n    <\/p>\n<p>\n      \u201cOncology is a priority area of focus for Merck and the acquisition of<br \/>\n      OncoEthix supports our strategy to prioritize the development of<br \/>\n      innovative molecules with the potential to improve the treatment of<br \/>\n      advanced cancers,\u201d said Dr. Roy Baynes, senior vice president, global<br \/>\n      clinical development, Merck Research Laboratories. \u201cThe potential<br \/>\n      first-in-class oral BET inhibitor, OTX015, has demonstrated early<br \/>\n      promising activity in hematological cancers and strategically<br \/>\n      complements our broad immuno-oncology development program.\u201d\n    <\/p>\n<p>\n      \u201cWe are delighted that OTX015 will now be in the hands of Merck, a<br \/>\n      company with a successful track record of developing cutting-edge<br \/>\n      therapies,\u201d said Bertrand Damour, chief executive officer, OncoEthix.<br \/>\n      \u201cThe acquisition underlines the promise that OTX015 has shown in the<br \/>\n      treatment of hematological malignancies, and the potential it has for<br \/>\n      the treatment of advanced solid tumors. We are confident that our<br \/>\n      transaction with Merck best positions OTX015 to be developed to its full<br \/>\n      potential in areas of high unmet medical need.\u201d\n    <\/p>\n<p>\n      BET proteins are considered potential therapeutic targets in cancer, as<br \/>\n      they play a pivotal role in regulating the transcription of key<br \/>\n      regulators of cancer cell growth and survival, including <i>c-Myc.<\/i><br \/>\n      Interim data from ongoing Phase I clinical studies of OTX015 have<br \/>\n      demonstrated meaningful clinical activity in patients with hematological<br \/>\n      malignancies. Interim data were recently presented at the American<br \/>\n      Association of Cancer Research (AACR) Annual Meeting in April 2014. An<br \/>\n      international, open-label Phase 1 study evaluating OTX015 in five<br \/>\n      different solid tumors was initiated in November 2014.\n    <\/p>\n<p>\n      Financial terms of the acquisition include an upfront payment of up to<br \/>\n      $110 million to OncoEthix. Additional milestone payments of up to $265<br \/>\n      million are contingent upon certain clinical and regulatory events being<br \/>\n      achieved.\n    <\/p>\n<p>\n      <b>About OncoEthix<\/b>\n    <\/p>\n<p>\n      Founded in 2009, OncoEthix is a Swiss-based privately held biotechnology<br \/>\n      company aiming to develop a small portfolio of oncology drug candidates.<br \/>\n      The Company\u2019s lead product, OTX015, is an investigational orally<br \/>\n      administered synthetic small molecule targeted to BET bromodomain<br \/>\n      proteins 2\/3\/4. OTX015 was in-licensed from Mitsubishi Tanabe Pharma<br \/>\n      Corporation in March 2012 following completion of Phase I clinical<br \/>\n      studies in healthy volunteers.\n    <\/p>\n<p>\n      OncoEthix has raised a total of US$30 million in venture capital to<br \/>\n      date: investors include Index Ventures, SV Life Sciences, Endeavour<br \/>\n      Vision and Edmond de Rothschild Investment Partners. For more<br \/>\n      information please see: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.oncoethix.com&amp;esheet=51005710&amp;newsitemid=20141218005052&amp;lan=en-US&amp;anchor=www.oncoethix.com&amp;index=1&amp;md5=6f082658f04ec0ee73d5bd43c34d3f17\" rel=\"nofollow\">www.oncoethix.com<\/a>.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into biomedical<br \/>\n      innovations to help people with cancer worldwide. For Merck Oncology,<br \/>\n      helping people fight cancer is our passion, supporting accessibility to<br \/>\n      our cancer medicines is our commitment, and pursuing research in<br \/>\n      immuno-oncology and other areas of breakthrough science is our focus to<br \/>\n      potentially bring new hope to people with cancer. For more information<br \/>\n      about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51005710&amp;newsitemid=20141218005052&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=642e895cf46658bcaa4c830e5bd8c85f\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51005710&amp;newsitemid=20141218005052&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=c8766f3f4e34154ef2981fe4f514326d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2F1jWVIedEI8Ie3D1Ob9KVJd5AsYeKCYedFEIzDxRSmkjqqb8VUttdVUSzt4QsEKnsohdG_6NmIblfGhbj_lgkoIIhfGgQ_BPpyON4-F3j-ndKKnojvovW_3AT-LsKCO-ZOb8UtORQr8EGTjjVkffGhBrwqrhdLCXCXCOsVHkiP9C9jDYunNnUSaCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96QrzztxwgD7GV&amp;esheet=51005710&amp;newsitemid=20141218005052&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=a2e40bdbed74637ef6152814745bf2c2\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2F1jWVIgdEI8Ie3D1Ob9KVJd5AsYeKCYedFEIzDxRSmkjqqb8VUttdVUSzt4QsEKnsohdG_6NmIblfGhbj_lgkoIIhfGgQ_BPpyON4-F3j-ndKKnojvovW_3AT-LsKCO-ZOb8UtORQr8EGTjjVkffGhBrwqrjdLCXCXCM0jKSYxmFnBYl-dyF3P7DDCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96Qrzzu-jj&amp;esheet=51005710&amp;newsitemid=20141218005052&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=48a61ef505cd7a20ca1c96764027389d\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2FavndzgA76Qm4m71PwV5ATsSCyOeu7nju76QQmhPMWXba9Jd5AsYeKCYYrhKyqeknbKc8CRvzoHm5GDR8BF_GEacmm8DR8qvOVINpoyvkxF_bCTnbI9LIfZvxOr_nKnjpvuV5AseVqWdAklrFFYG7DR8OJMddICTPtPtPo08JlKrp3-nNnUSaCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96QrzzqvgF&amp;esheet=51005710&amp;newsitemid=20141218005052&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=804740fdb5ff3c8ed60b172a6007fa16\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51005710&amp;newsitemid=20141218005052&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=6992b933985c0d876b64c1f30424e85a\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141218005052r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Claire Mulhearn,        908-236-1118<br \/>or<br \/>Investors:<br \/>Joseph Romanelli, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acquisition Expands Merck\u2019s Oncology Portfolio with Novel Oral BET Inhibitor, OTX015 Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors. \u201cOncology is a priority area of focus for Merck and the acquisition of OncoEthix supports our strategy to prioritize the development of innovative molecules with the potential to improve the treatment of advanced cancers,\u201d said Dr. Roy Baynes, senior vice president, global clinical development, Merck Research Laboratories. \u201cThe potential first-in-class oral BET inhibitor, OTX015, has demonstrated early promising activity in hematological cancers and<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744871","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Acquisition Expands Merck\u2019s Oncology Portfolio with Novel Oral BET Inhibitor, OTX015 Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors. \u201cOncology is a priority area of focus for Merck and the acquisition of OncoEthix supports our strategy to prioritize the development of innovative molecules with the potential to improve the treatment of advanced cancers,\u201d said Dr. Roy Baynes, senior vice president, global clinical development, Merck Research Laboratories. \u201cThe potential first-in-class oral BET inhibitor, OTX015, has demonstrated early promising activity in hematological cancers and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:47+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141218005052r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\\\/\",\"name\":\"Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141218005052r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2014-12-18T07:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141218005052r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141218005052r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/","og_locale":"en_US","og_type":"article","og_title":"Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers - Merck.com","og_description":"Acquisition Expands Merck\u2019s Oncology Portfolio with Novel Oral BET Inhibitor, OTX015 Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors. \u201cOncology is a priority area of focus for Merck and the acquisition of OncoEthix supports our strategy to prioritize the development of innovative molecules with the potential to improve the treatment of advanced cancers,\u201d said Dr. Roy Baynes, senior vice president, global clinical development, Merck Research Laboratories. \u201cThe potential first-in-class oral BET inhibitor, OTX015, has demonstrated early promising activity in hematological cancers and","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:47+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141218005052r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/","name":"Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141218005052r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2014-12-18T07:30:00+00:00","dateModified":"2023-03-22T04:04:47+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141218005052r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141218005052r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-acquires-oncoethix-a-privately-held-oncology-company-developing-novel-bet-inhibitors-for-hematological-and-solid-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"2acebebe-43cf-4583-8737-8ae2e7f8de6c","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Acquires-OncoEthix-a-Privately-Held-Oncology-Company-Developing-Novel-BET-Inhibitors-for-Hematological-and-Solid-Cancers-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744871\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744871"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}